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The mechanism of N-methyl-izatin-thiocarbazone (methisazone, Mel ВТ) antiviral 
activity has been studied on Ad 1-infected HEp2 and HeLa cells. Mel ВТ did not induce 
interferon and did not directly inhibit viral and cell translation. The adenoviral infection 
was not affected by recombinant human interferon a2 (rIFN). Mel ВТ showed antiviral 
effect in AdI-infected HEp2 or HeLa cells when rIFN had added to HeLa cells or in the 
period of interferon induction during virus infection (in HEp2 cells). In the presence of 
this compound, the El A transcription was unchanged in infected cells as compared to 
untreated control, while early transcription was decreased, the beginning of viral 
replication being retarded. Futhermore, the VAI RNA synthesis was also greatly 
suppressed. These effects were independent on interferon treatment and disappeared 
when MeIВТ had been added during the late phase of virus growth cycle. Actually, MeIВТ 
can induce the delay of VAI RNA transcription promoting interferon antiviral effect 
Introduction. Methisazone (N-methyl-isatin-/i-thiosemicarbazone, N-MeIBT, 
MelBT) is a known antiviral drug studied earlier [1 ]. Izatizon is an original 
liquid form of MelBT [2] . Both izatizon and MelBT possess a large spectrum 
of antiviral action, but izatizon is more effective (20-100 times higher than 
MelBT) and demonstrates no toxic effects in therapeutical doses. Izatizon has 
b e e n shown as a n ant ivi ra l agen t aga ins t poxvi ruses , he rpesv i ru se s , 
enteroviruses, influenza viruses A and B, e t c After optimal schemes of drug 
application, 100 % curability was reported. So, the antiviral action of both 
MelBT and izatizon in vitro is identical [2] . 
T h e methisazone directed mechanism of cell defence is not known. Earl ier 
published data demonstra te that MelBT reduces the late post-replicative protein 
synthesis in virus-infected cells [3—6 ]. In the presence of this compound, a 
disruption of polysomes in vaccinia virus-infected cells has been also observed 
[7 ]. However, MelBT induced no effect on in vitro t ranslation [8 ], It inhibited 
different DNA- a n d RNA-viruses [9 ] . The antiviral effect has been observed 
by treat ing the adenovirus-infected cells with MelBT during the early phase of 
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infection [10] . MelBT also showed a slight suppressive action on RNA-
synthesis [8 ] . Early studies have not detected the target of methisazone action 
in virus-infected cells. The activity of MelBT against vaccinia virus was 
disappeared when cell transcription had been blocked by actinomycin D [4 ] . 
So, MelBT cannot provide antiviral action without cell transcription. Moreover, 
whereas the existence of MelBT-dependent and MelBT-resis tant mutants of 
vaccinia virus has been also reported [11] , it is likely some viral gene /pro te in 
a re methisazone targets , the latter being cooperated with a cellular gene (or 
genes) . 
Here we demonstrate that MelBT is capable to reduce a viral defence 
against interferon antiviral action. Since MelBT does not inhibit the adenoviral 
infection without interferon, interferon is a cellular compound necessary for 
methisazone directed cell defence mechanism. 
Materials and Methods.MelBT was synthesized as described previously 
(see [2 ] ) . To test its action, the compound was dissolved in dimethyl sulfoxide 
(or in mixture DMSO:PEG400, 1:3, v /v ) , stock concentration being 10—100 
mM; it was added to culture medium after virus absorption at different final 
concentrations (0.001—50 mM). T h e final concentration of each solvent was not 
higher than 0.5 % . No toxic effects of solvents were observed up to 2 % 
concentration. 
C e l l s (HeLa and HEp2) were grown in the minimal essential Eagle 
medium supplemented with 10 % fetal calf serum, 1.2 mM glutamine and 0.2 
% sodium bicarbonate, and a mixture of penicillin.streptomycin (up to 100 
un i t s /ml :40 mg/1) . T h e cells were infected with human adenoviruses — Ad HI 
3H10 (Adl ) and Ad H2 (Ad2) with a moiety of infection 5 P F U per cell. After 
incubation at 37 °С, the Ad-infected cells were microscopically tested, washed 
by PBS, frozen at -70 °С and kept until futher studies. 
I n t e r f e r o n enzyme immunoassay. Polychlorvynil 
plates (Titertek Immuno Assay-Plate , «Flow Laboratory») were used. Polyclonal 
an t i - IFN antibodies were obtained from Research Insti tute of Hyperpure 
Biopreparations (St. Petersburg, Russian Federat ion) . They were dissolved 
(5 mg /ml ) and absorbed on the plates in 0.1 M sodium carbonate-bicarbonate 
buffer, pH 9.6, during 24 h at 45 ° С Free binding sites were blocked by 
0.1 % bovine serum albumin (BSA) in the same buffer( 1 h , 37 °С). Standard 
IFN a2 (N. F. Gamaleya Epidemiology and Immunology Insti tute, Moscow) and 
tested probes were added in the PBST-BSA-0.1 buffer (solution containing 
0.01 M K-phosphate , 0.15 M NaCl , 1 mM MgCl 2 , a n d 0.05 % Tween 20, 
0.1 % BSA, pH 7.0, 100 ml, 1 h, 37 °С). Then the conjugate (at the dilution 
1:400, 100 ml) was added , the probes being incubated 1 h at 37 °С. Finally, 
the fluorogenic substrate ( 0 . 0 1 % water solution of 4-methylumbell ipheryl-^-
D-galactoside, 100 ml) was added, and after 2 h (37 °С) the reaction was 
stopped by adding 0.1 M NaOH-glycine buffer, pH 10.3 (100 ml) . T h e 
fluorescence of probes was measured using Hitachi-850 spectrofluorometer 
(exitation 360 nm, emission 450 n m ) . After each step of incubation, microplates 
were washed 3 times by PBST buffer at room temperature . The conjugate of 
an t i - IFN a2 monoclonal antibodies with ^-galactosidase was obtained according 
to protocol of Boehringer Mannheim Biochemica Co. 
The viral protein immuno assay. T h e ant iserum against 
Ad6 was obtained by intramuscular immunization of rabbi ts . T h e purification 
of t h e h e x o n A d l was provided by hyd rophob ic a n d ion ex ch an g e 
chromatography on the columns with buthyl-toyopearl («Toyosoda») and 
DEAE-Trisacryl («Pharmacia»). T h e purified hexon A d l was used for the 
performance of calibration curve. 
T h e sandwich ELISA modification in polystyrol plates («Linbro») was used. 
Monoclonal antibodies against hexon A d l were dissolved (10 mg/ml ) and 
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Fig. 1. The level of hexon synthesis in 
Adl-infected HEp2 cells (a) and HeLa cells 
(b) during virus growth cycle. MelBT (2.5 
mM) a n d rIFN ( 1 0 0 0 U / m l ) w e r e 
supplemented to the culture medium at 1 h 
p. i. Hexon assay were performed in the 
extracts of infected cells ( 1 0 ъ cells in each 
variant) frozen at - 7 0 °С. Values represent 
the mean of 3 determinations. J — Control; 
2 — MelBT; 3 — MelBT + rIFN; 4 — rIFN 
absorbed on the plates as earlier (see upper) . Then the plates were washed 3 
times by PBST buffer and incubated in PBS (with 1 % BSA) (30 min, 37 °С). 
T h e cell lysates (1:10, 100 ml) in PBST buffer were added (1 h, 37 °С), the 
rabbit serum against Ad H6 (100 ml) was added and incubated (1 h, 37 °С). 
After washing, the HRP-conjugated goat antibodies against rabbit IgG (N. F . 
Gamaleya Epidemiology and Immunology Institute, Moscow) were diluted 
(1:100) a n d added (100 ml) too. After incubation during 1 h at 37 °С H P R 
activity was determined by adding of hydrogen peroxide (up to 0.015 %) and 
o-phenylendiamine (up to 0.4 mg/ml) in 0.1 M phosphate-citrate buffer, pH 
5.0. T h e reaction was stopped by adding of 4 N H 2 S 0 4 (50 ml) . T h e optical 
densities of probes a re measured at 490 nm using Dynatech MR700 photometer. 
DNA c l o n i n g , DNA Ad2 was extracted according to [12] . Ad2 
DBP-containing fragment (nt 23767 to 24103/.Sau3A s i tes / ) was excised from 
pAdR4.3 plasmid constructed by cloning of EcoRl B-fragment (nt 21338 to 
25633) from total Ad2 DNA in the EcoRl site of plasmid pUC19. Then the 
336 bp DBP-fragment was cloned in the BamHI site of pUC19 (pDBPO.3). 
To clone VAI RNA gene, the Hindlll B-fragment (nt 6231 to 11555) Ad2 
DNA was excised and cloned in the HindUl site of pUC19 (pAdH5.3). On the 
second stage, the Alul 548 bp fragment was extracted and cloned in the SmaI 
site of pUC19 {pVA\54%). On the third stage, the plasmid pVA224 was obtained 
(nt 10255 / Alul s i t e / to 10479 /Xbal s i te / ) by removing XbaI-fragment from 
pVAI548. 
To test E l A transcription, the synthetic oligonucleotide probe was 
synthesized (nt 831 to 853 of Ad2). 
Hybridization procedures. RNA preparations from infected 
cells were extracted as described [13]. VAI RNA was purified according to 
O'Malley et al. [14] . The DNA probes were labelled by nick-translation 
Promega kit with a - 3 2 P - d C T P to a specific radioactivity of (1—5) -10 s c p m / m g 
of DNA. Electrophoresis of the denatured RNA samples in 2 % agarose gels 
containing 2 % formaldehyde, blot-transfer to Hybond N membrane , DNA-
DNA and DNA-RNA hybridization to the 3 2 P-label led DNA probes were 
performed as described previously [15] . Filters were dissected and radioactivity 
of hybridized probes was detected according to Cerencov program. 
Results . T h e cytotoxicity of MelBT was usually observed with drug 
concentration above 40 mM. The lower concentrations were inhibiting for the 
viral protein synthesis in a dose-dependent manner as expected from earlier 
results [10] . T h e sensitivity of Adl to MelBT in vitro action was determined 
by immunoassay method. Our data concerning drugs have been shown no 
differences between MelBT and izatizon in vitro action. T h e decreasing of viral 
hexon synthesis was observed in МеІВТ-treated Adl- infected HEp2 cells (Fig. 
1, я ) . T h e recombinant human interferon a2 (rIFN) did not damage hexon 
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Fig. 2. The expression of interferon a2 in Adl-infected HEp2 cells. MelBT (2.5 mM) was 
supplemented to the culture medium at 1st h post infection; a — DNA-RNA dot-hybridization of total 
RNA of Adl-infected cells ( 1 0 5 cells in each variant) was performed with nick-translated probe 
pIF226; b — interferon a2 was determined in culture media by immunofluorescence assay during virus 
growth cycle (7 — HEp2, control; 2 — HEp2, MelBT; 3 — HeLa. MelBT). Values represent the 
mean of 3 determinations 
synthesis was observed at the 5th h. Later the level of interferon increased, and 
the second maximum of interferon appeared at the 20-21th h p . i. After 40 h, 
the third maximum was also revealed. Existence of more than one maximum of 
interferon induction shows the possibility of virus reinfection beyond each virus 
growth cycle (16—18 h in our experiments) . T h e infective process developed 
completely on the third day. Almost all the cells were infected and aggregated. 
On the contrary, Ad l induced tenfold lower interferon titer in HeLa cells as 
compared to HEp2 ones (Fig. 2, b). The same results have been also obtained 
with HeLa S3 cells and Vero cells (data not shown). T h e drop of interferon 
expression correlates to the absence of MelBT antiviral action in virus-infected 
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synthesis , however MelBT antiviral effect increased in the presence of r IFN. 
On the other hand , the level of hexon accumulation did not decrease in 
МеІВТ-t rea ted Adl- infected HeLa cells as compared to untreated culture 
(Fig . l , b). T h e r IFN did not also inhibit the adenoviral infection in HeLa cells. 
However, in the presence of both MelBT and r IFN, the antiviral effect appeared 
again (Fig. 1, b). Hexon accumulation in adenovirus-infected cells was sharply 
inhibited when the addit ion of MelBT (+ r IFN) is delayed until 8 h post 
infection (p. L). Increasing amounts of viral hexon appeared when addit ion of 
the drug is delayed beyond this time (not shown). Since adenoviruses are not 
sensitive to interferon antiviral effects, it is likely the antiviral activity of MelBT 
is due to activation of both early viral functions and interferon expression. 
In the absence of MelBT, Ad l stimulated interferon expression in HEp2 
cells beginning from the 2nd h p. i. (Fig. 2, a ) . T h e maximum of interferon 
* Е С 5 0 — concentration providing 50 % inhibition of virus yield at the 24th h p. i.; * * I D 5 0 — 
concentration providing 50 % inhibition of cell viability (measured by NTT-test); ***NA — not 
affected. 
HeLa ceils, and virus hexon synthesis was greatly reduced by simultaneously 
adding of r IFN and MelBT (see Fig. 1, b and table) . 
MelBT influenced on the induction of interferon in Adl- infected HEp2 cells 
(Fig. 2 ) . T h e interferon expression being low until 8th h p. i. increased sharply 
after 8—9 h p. L a n d became further depressed after 12—14 h p . i. Another 
Fig. 3. MelBT retards early transcription (a) and viral replication (b) in Adl-infected cells. The 
extracts of Adl-infected MelBT (2.5 mM)-treated and untreated HEp2 cells (106 cells in each 
variant) were hybridized with nick translated DNA Ad2. The radioactivity of dissected filters was 
measured according to Cerencov program. 1 — Control; 2 — MelBT 
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Fig 4. The accumulation of D B F - (a), El A- (b), and VAI RNA- (c) transcripts during virus growth 
cycle in Adl-infected HEp2 cells. The extracts of Adl-infected MelBT (2.5 mM)-treated and 
untreated HEp2 cells (10° cells in each variant) were hybridized with nick-translated DNA; a— 
D N A - R N A dot probed with pDBP0.3; b — DNA-RNA dot-hybridization with synthetic 
oligonucleotide probe ( E l А ) ; с — to test VAI RNA, the nick-translated probe pVA224 was used; 1 — 
Control; 2 — MelBT 
growth cycle has revealed that drug re tards the beginning of viral DNA 
synthes is in Adl- infected cells as compared to untreated cells (Fig. 3 , b). This 
effect was obtained when MelBT has been added until 8th h after infection, 
a n d disappeared when MelBT has been added later. So, MelBT cannot directly 
inhibit viral replication. Since the viral DNA-polymerase mRNA is transcribed 
from the early region of adenoviral genome [16] , it is likely this effect of 
compound follows the delayed early transcription. 
maxima of interferon synthesis were slight. T h e appearence of virus cytopathic 
effect was delayed. Since MelBT (as well as izatizon) does not induce any type 
of interferon in vitro and in vivo [2 ] , and possesses no direct action on 
translat ion [8] we conclude that this compound might act on the early viral 
transcription resulting to be the modification of interferon expression in 
virus-infected cells. 
T h e possible mechanism of MelBT action makes predictions re tarding the 
beginning ng of early viral transcription. Accordingly, we measured amounts of 
total viral RNA and viral DNA in extracts of with and without MelBT-t rea ted 
infected or uninfected cells (HeLa and HEp2) by dot-hybridization method. In 
control cells no hybridization signal has been detected. After infection the 
amounts of viral RNA greatly increased especially from the beginning of the 
late phase of virus growth cycle (Fig. 3, a ) . After MelBT treatment the 
accumulation of early viral RNA was 7—10 fold reduced (Fig. 3 , a) as compared 
to untreated Adl- infected cells up to the 8th h p. i., and increased beyond this 
t ime. As found previously on the model of vaccinia virus-infected cells [8 ] , the 
50 per cent inhibition of transcription has been also observed during the late 
phase of virus growth in MelBT-treated culture. Moreover, the time of half-life 
of R N A transcripts was identical in MelBT-treated and untreated cells [8 ]. T h e 
delay of viral transcription appeared if MelBT had been added until 8 h p. i. 
and disappeared when MelBT had been added later. 
Earlier it has been shown that MelBT does not inhibit vaccinia virus 
replication [5] . T h e equal amounts of adenoviral DNA were observed in 
MelBT-t rea ted cells and in untreated ones only on the late infection phase 
(18 h p. i.). However, the analysis of Adl DNA accumulation during the virus 
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Fig. 5. MelBT effect on VAI RNA synthesis. The RNA of Adl-infected cells ( l ( f cells in each variant) 
was extracted at the 16th h p. i. and run in electrophoresis. VAI RNA analysis was provided by 
Northern blot probed with pVA224 a — V A I RNA of Adl-infected HEp2 cells. 10 ng purified VAI 
RNA (line 1) was presented. MelBT (2.5 mM) was added (line 2) or not (line 3) in the culture 
medium at the 1st h p. i. The low molecular RNA of Adl-infected HEp2 cells (the 1st h p.i. ) is also 
presented (line 4); b — 50 ng of purified VAI RNA was added (line / ) . VAI RNA of Adl-infected 
untreated HEp2 cells (line 2 ) , and VAI RNA of Adl-infected HEp2 cells when MelBT (2.5 mM) and 
rIFN (1000 U/ml) were simultaneously added at the 8th h (line 3) and at the 1st h (line 4) p. i; с 
— VAI RNA analysis in Adl-infected HeLa cells. 50 ng purified VAI RNA was run (line 7) . MelBT 
(2.5 mM) was added (line 2) or not (line 3) at the 1st h p. i. 
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In addit ion, the same effect of MelBT was shown by testing DBP-gene 
transcription in Adl- infected cells. Hence, the accumulation of DBP-transcripts 
was reduced in МеІВТ-treated cells as compared to untreated culture during 
8—10 h p . i. (Fig. 4, a). 
To test whether MelBT treatment influenced on the transcription of early 
A d l 1A region ( E l A ) , the amounts of E1A RNA were measured in Adl- infected 
cells during virus growth using dot-hybridization with polynucleotide kinase-
phosphorylated oligonucleotide probe. Our experimental data showed no 
influence of compound on E l A transcription (Fig. 4, b). 
Since MelBT depresses early transcription and viral replication in A d l -
infected HEp2 , HeLa, and HeLa S3 cells with and without interferon, it proves 
MelBT functions to be interferon-independent. 
Adenoviruses a re relatively resistant to interferon challenge [14] , T h e loss 
of interferon antiviral activity is due to P l / e I F 2 kinase inhibition by viral VAI 
RNA. In the presence of interferon and small quantities of dsRNA, the kinase 
can phosphorylate initiation factor eIF2 inducing polysomes disruption and 
blocking translation [14] . Earlier, the VAI RNA synthesis by RNA-polymerase 
III has been shown after viral replication beginning [16] . Since the viral 
DNA-synthesis was re tarded in МеІВТ-treated cells, we have proposed VAI 
RNA-gene transcription to decrease. To test the level of VAI RNA synthesis , 
the dot-hybridization has been used. Our data have been demonstra ted VAI 
R N A accumulation to be re tarded and reduced in МеІВТ-treated Adl- infected 
HEp2 cells as compared to untreated Adl- infected cells (Fig. 4, c) . These data 
w rere completely confirmed by Northern analysis of VAI RNA (Fig. 5, a ) . The 
loss of VAI RNA was not observed when the addition of drug has been provided 
on the late phase of virus growth cycle (Fig. 5, b). So, it is evident the antiviral 
agent does not directly suppress VAI RNA synthesis and RNA-polymerase III 
activity. T h e r IFN has also shown no effect on VAI RNA transcription (Fig. 5 , 
b). Moreover, the drop of VAI RNA transcription was appeared in MelBT-
treated Adl- infected HeLa cells (Fig. 5, c) when the adenoviral infection was 
МеІВТ-resis tant , and the Adl induced the low titer of interferon. 
AROMATIC THIOSEMICARBAZONES, THEIR ANTIVIRAL ACTION 
81 
Discussion. Our experimental data show that the main action of MelBT is 
related with the delay of both early adenoviral transcription and adenoviral 
replication. Since MelBT does not inhibit the viral protein synthesis without 
interferon and interferon does not inhibit viral infection without the drug, it is 
evident that MelBT can suppress the viral defence against interferon action. 
Actually, interferon is the necessary cell compound participating in the MelBT 
directed mechanism. How common is such a mechanism restoring interferon 
action? According to [14] , the virus protection against interferon is dependent 
on VAI R N A which can inhibit interferon activated P l / e I F 2 kinase. T h e virus 
defence against interferon action is developed when large amount of VAI RNA 
appear during the late phase of virus growth cycle. Since the level of VAI RNA 
synthesis is sharply reduced in MelBT-treated Adl- infected cells, a high 
concentration of interferon is capable to increase the initiation of factor eIF2 
phosphorylat ion balloned by translation blocking. Moreover, the ra te of 
translation was greatly stimulated in cell-free extracts from MelBT+interferon-
t reated Adl- infected cells when the purified eIF2 was added (data not shown). 
T h e mode of MelBT action described here may be appropriate for another 
DNA- and RNA-viruses. In addit ion, we can suggest about the correlation 
between the interferon-inducing ability of viruses and the antiviral effect of this 
compound. Moreover, some other МеІВТ-susceptible viruses [9] possess an 
analogous protective mechanism against interferon action [17] . Besides, 
methisazone does not significantly prevent the production of viral antigen by 
cells a l ready chronically infected with HIV-1 . However, in the presence of 
r I F N , the compound (nontoxic concentrations) can reduce the yield of infective 
virus in this culture by 10—100 fold. 
T h e viral target of MelBT is still unknown. Since the MeiBT-resis tant 
mutan ts of vaccinia virus has been obtained earlier [11] , it is probable the 
existence of one virus gene/protein- target of MelBT. Our experiment showed 
the delay of early transcription in MelBT-treated Adl- infected cells, but the 
transcription of early region A l was not significantly changed. A protein 
encoded in E l A region promotes the rapid onset of viral transcription. This 
phosphoprotein predicted from the sequence of its mRNA is to be 289 amino 
acids long (289 pp) and required to facilitate early transcription [18] . Moreover, 
it contains a zinc-binding region [19] . On the other hand , MelBT is known as 
an effective chelating agent [20] which binds preferentially cations Zn 2* and 
C u 2 + , It is tempting to speculate that MelBT might function by suppressing the 
289 pp activity. 
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Ароматичні тіосемікарбазони, їх антивірусна дія та інтерферон. 1. Зниження стійкості 
аденовірусу 1-го тину до інтерферону в присутності метисазону in vitro 
Резюме 
Вивчали механізм реалізації антивірусного ефекту N-метил-ізатин-тіосемікарбазону 
(метисазону) на моделі аденовірусної (аденовірус людини І типу) інфекції in vitro. Показано, що 
репродукція вірусу резистентна до рекомбінантного інтерферону а2 людини, а метисазон 
пригнічує вірусну інфекцію лише в присутності інтерферону — ендо- або екзогенного. 
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Тестуванням синтезу вірусної ДНК та РНК, а також експресії окремих вірусних генів методами 
дот- і Нозерн-гібридизації встановлено, що метисазон затримує транскрипцію «ранніх» генів 
аденовірусу. Це призводить до затримки початку реплікації вірусу і зменшує концентрацію VAI 
РНК. Оскільки кількість VAI РНК визначає рівень стійкості аденовірусу до інтерферону, то, 
очевидно, що метисазон посилює деструктивний вплив інтерферону на синтез вірусних білків. 
Ю. В. Пацковский, Э. Н. Негребецкая, А. А. Черномаз, Т. П. Волощук, Е. Л. Рубашевский, 
О. Э. Китам, М. И. Терещенко, Л. Н. Носач, А. И. Потопальский 
Ароматические тиосемикарбазоны, их антивирусное действие и интерферон. 1. Снижение 
устойчивости аденовируса 1-го типа к интерферону в присутствии метисазона in vitro 
Резюме 
Изучен механизм реализации антивирусного эффекта N-метил-изатин-тиосемшсарбазона 
(метисазона) на модели аденовирусной (аденовирус человека 1-го типа) инфекции in vitro. 
Показано, что репродукция вируса резистентна к рекомбинантному интерферону а2 человека, а 
метисазон угнетает вирусную инфекцию только в присутствии интерферона — эндо- или 
экзогенного. Тестированием синтеза вирусной ДНК и РНК, а также экспрессии отдельных 
вирусных генов методами дот- и Нозерн-гибридизации установлено, что метисазон 
задерживает транскрипцию «ранних» генов аденовируса. Это приводит к задержке начала 
репликации вируса и уменьшает концентрацию VAI РНК. Поскольку количество VAI РНК 
определяет уровень устойчивости аденовируса к интерферону, то, очевидно, что метисазон 
усиливает деструктивное влияние интерферона на синтез вирусных белков. 
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